XOMA Corporation (XOMA) - מכפיל EV/EBITDA
The market price confirmed by this chart demonstrates an EV/EBITDA multiple of 92.49, highlighting the role of XOMA (XOMA) as a financial ally to the biotech sector through the acquisition of rights to future payments. The business relies on an asset-light model, accumulating patents and milestone bonuses without incurring research costs. This structure provides full protection against inflation and expenses by linking profits to the market success of partners' drugs.
פילוחי מדדים ואנליטיקה של חברת xoma.com (XOMA)
XOMA Royalty specializes in antibody licensing and high-tech biomedical analysis. This metric compares the total enterprise value with its operating income, neutralizing the impact of debt load and taxes. The price action of the EV/EBITDA valuation multiple reflects the market's revaluation of scientific capital between quarterly reports. Monitoring this metric allows an investor to promptly identify the fundamental undervaluation of assets and avoid the risks of portfolio overconcentration.
